Saturday, October 1, 2022


Biotechnology News Magazine

Orca Therapeutics: Reports to Start Highest Dose in Treatment-naïve Prostate Cancer

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

March 9, 2021

ORCA Therapeutics B.V., based in the Netherlands, is a clinical-stage biopharmaceutical company developing oncolytic viruses to treat solid tumors.

Today the company announced upon review of all safety data from the fully enrolled, low- and mid-dose patient cohorts of the ongoing Phase 1/2a clinical study of ORCA-010 in treatment-naïve patients with localized prostate cancer, the independent Data and Safety Monitoring Board (DSMB) unanimously recommended the continuation of the study without modification.

From this recommendation, ORCA Therapeutics will initiate administration of the highest scheduled dose level of ORCA-010 in the single dose part of the study.

Following this recommendation, ORCA Therapeutics B.V. has commenced enrollment in the highest-dose arm of the dose-escalation phase of this study, with the first patient scheduled for administration in March 2021.

Upon conclusion of enrollment in the highest study arm, DSMB will conduct an additional review on ORCA-010 prior to starting the repeat dosing part of the trial.

At the lowest dose studied, ORCA-010 demonstrated strong single-agent antitumor activity in the first patient. Further, MRI data reflected an impressive and significant decrease in prostate volume returning to normal size, as well as continuing decreases in PSA. This pattern has been confirmed in the second patient who completed the 6-month follow-up MRI, and also showed prostate volume returning to near normal size.

Investors favorably viewed the DSMB recommendations and the recent clinical success by investing in another round of financing to progress ORCA-010’s development. ORCA-010 has garnered the attention of researchers, recently, ORCA Therapeutics B.V. has initiated discussions to prepare for a study in patients with unresectable/medically inoperable esophageal cancer.

“12% of all men will be diagnosed with prostate cancer in their lifetime. We are encouraged by the safety profile and preliminary efficacy of ORCA-010 and are excited to continue enrollment in the highest dose cohort of this Phase 1/2a study, our first clinical study with ORCA-010,” said Kees Groen, ORCA Therapeutics’ CEO. “We are grateful for the continuous support from our investors.  The generous contributions enable ORCA Therapeutics to progress ORCA-010’s development for treating prostate cancer.”

ORCA Therapeutics B.V.’s two-part Phase 1/2a study is a multi-center, open-label, dose-escalation study of ORCA-010 in approximately 24 treatment-naïve patients with localized prostate cancer:

Part A: Dose-escalation phase to define the safety, tolerability, and optimal dose level of ORCA-010 in treatment-naïve patients with localized prostate cancer. This phase is expected to enroll up to 12 patients in three dose cohorts.

Part B: A subsequent extension of the optimal dose level, as defined in the dose escalation phase, and given as two doses with 2 weeks interval. This phase is expected to enroll approximately 12 additional patients.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine